How to use Technologies offered

A search for a cancer, preclinical stage, synthetic opportunity would use the selection "Therapeutics, Diagnostics" in 'Sector', 'Cancerous, neoplasmatic' in 'Disease Category', 'Drugs, Small Molecule' in 'Technology' and 'Preclinical' in 'Development Stage'.

Selection of 'Enabling Technology, Platform Technology' in 'Sector' will identify all kinds of research technologies that can be used in more areas of life sciences than pharmaceuticals only.

Each technology profile gives the name of a company or academic institute as source of the offer, and a link allowing to contact the potential licensor. In most cases a profile includes a pdf covering the available non-confidential information as well as detailed contact data.

Registered users can create non-public notifications profiles which will inform them about new 'Technologies Offered' entries fitting their needs as specified. In addition these profiles allow them to filter the available information more comfortably.

Name

Phosphate Binder for the Treatment of Hyperphosphatemia

Organization name

ipal GmbH

Profile

Background

Hyperphosphatemia is a complication of chronic kidney disease. Patients with renal insufficiency have an abnormal phosphate metabolism that leads to an elevated concentration of phosphate in the blood. In conjunction with calcium imbalance, hyperphosphatemia increases the risk of cardiovascular disease in patients with renal failure.

Hyperphosphatemia promotes arterial calcification which increases the risk of myocardial infarction and is therefore a big risk factor for cardiovascular mortality in dialysis patients. Due to the problems of current phosphate binders like poor taste, halitosis, gastro-intestinal complaints and high cost, there is a great demand for novel phosphate binders.

Technology

We offer a phosphate binder on the basis of maghemite or maghemite/ magnetite. The novel phosphate binder comprises an iron oxide core being coated with carbohydrates e.g. sugar molecules like mannose or fructan. The iron oxide core is less than 20 nm in diameter and shows an inverse spinel structure, which offers a high phosphate binding capacity.

Benefits

  • Highly improved phosphate binding capacity
  • Well tolerated oral phosphate binder
  • No known side effects
  • Low manufacturing costs
  • Easy to manufacture

IP Rights

DE, US patent application (09/2011)
PCT patent application

Patent Owner

Charité Universitätsmedizin Berlin

To view the contact information, attachments and url of this profile you have to login into your account or register a new account: Login Register

Your feedback

Please click here to log in to view the complete profile.

 
 

latest entries